Vascular Screening Devices Market By Product (ABI and TBI Systems, Handheld Vascular Dopplers, Duplex and Color-Doppler Ultrasound Systems, Pulse-Volume Recording and Photoplethysmography Systems, Cuffs, Probes, Software and Accessories); By Application (Peripheral Artery Disease Assessment, Abdominal Aortic Aneurysm Screening and Surveillance, Carotid Artery Assessment, Post-Revascularization Monitoring, Diabetic-Foot and Wound-Related Vascular Assessment); By End User (Hospitals and Vascular Laboratories, Diagnostic Imaging Centers, Cardiology and Vascular-Surgery Clinics, Primary-Care Practices, Podiatry, Diabetes and Wound-Care Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Vascular Screening Devices Market: Disease Burden, Surveillance Demand and Outpatient Testing Expand Commercial Opportunity

The Global Vascular Screening Devices Market is valued at USD 2.27 billion in 2025 and is projected to reach USD 3.86 billion by 2032, expanding at a CAGR of 7.9%, according to Strategic Market Research.

 

A reusable ABI or ultrasound platform may perform hundreds or thousands of examinations during its working life. Vascular screening devices are non-invasive medical tools designed to detect arterial stiffness, measure blood flow velocity, and calculate the Ankle-Brachial Index (ABI) to identify conditions such as Peripheral Artery Disease (PAD). By using technologies including ultrasound, photoplethysmography, and pressure cuffs, these systems enable early cardiovascular risk assessment and help prevent severe complications such as limb amputations. Their ability to deliver rapid, repeatable results makes them essential across both diagnostic and preventive care settings.

 

Leading manufacturers are expanding product portfolios to address both clinical and portable screening needs. CorVascular Diagnostics offers the FDA-cleared VasoGuard V-Series (models V2 through V10), which integrates wearable photoplethysmography sensors with continuous-wave Doppler probes for PAD and peripheral vascular disease testing. ARTSENS, developed at IIT Madras, provides ARTSENS Plus and ARTSENS Pen systems that use image-free ultrasound technology to evaluate carotid artery stiffness, aortic pulse wave velocity, and vascular age. SOT Medical’s AngE™ ABI+ device automates ABI calculation and vascular health scoring through pulse volume and pressure tracking, while OMRON Healthcare’s VP-1000plus delivers comprehensive automated ABI and pulse wave velocity assessments within minutes. These innovations highlight the shift toward integrated, user-friendly platforms that support early detection and scalable screening programs.

 

Peripheral Artery Disease Creates the Largest Addressable Patient Pool

Peripheral artery disease provides the broadest underlying demand base. The CDC estimates that about 6.5 million people aged 40 and older in the United States have PAD. Globally, an ABI-based systematic review estimated 236.62 million cases among adults aged 25 and older in 2015. About 72.91% were located in low- and middle-income countries, indicating that most clinical need exists outside the highest-spending medical-device markets. A separate Global Burden of Disease analysis reported about 113.44 million prevalent cases in 2019, reflecting a different definition and modeling approach.

Portable and automated systems can extend testing beyond specialist vascular laboratories. Primary-care and foot-care providers often encounter circulation problems before specialist referral, while access to ABI, TBI, Doppler and waveform assessment can support earlier referral decisions.

 

Multi-Mode Testing Is Becoming More Valuable Than Basic ABI Alone

ABI testing offers a relatively simple and low-cost way to identify reduced leg blood flow. However, ankle measurements can be difficult to interpret in patients with diabetes, chronic kidney disease or calcified arteries. These limitations support demand for toe-brachial index testing, pulse-volume recordings, Doppler waveforms and segmental-pressure measurements.

D. E. Hokanson, Newman Medical, Viasonix and MESI offer systems covering combinations of ABI, TBI, Doppler, pressure and waveform assessment. The competitive focus is shifting from single-test instruments toward integrated physiological platforms that serve different patient conditions and care settings.

One published segment forecast places portable vascular screening devices at USD 1.4 billion by 2030, equal to roughly 64% of its projected market, with a 4.9% CAGR from 2024 to 2030. The corresponding standalone segment represents approximately USD 0.8 billion, or 36%, in 2030 and is projected to expand at 2.9%. This product mix supports the movement of testing into outpatient, community and lower-infrastructure settings.

 

Abdominal Aortic Aneurysm Supports Organized Screening and Repeat Surveillance

Abdominal aortic aneurysm offers the clearest preventive screening pathway. In the United States, the USPSTF recommends one-time ultrasound screening for men aged 65 to 75 who have ever smoked and selective screening for some men in the same age group who have never smoked.

A U.S. evidence review reported about 200,000 AAA diagnoses annually, including roughly 15,000 aneurysms considered large enough to carry a high risk of rupture. Ultrasound is suited to outpatient and community screening because it is non-invasive and widely available.

During England’s 2024–2025 national program, 337,752 men were offered screening, 82.3% were tested and 1,907 aneurysms were detected. At year-end, 14,696 men were under surveillance and 22,931 surveillance scans had been performed.

More than 90% of aneurysms identified through screening are below the usual threshold for immediate surgery and generally enter periodic ultrasound surveillance. Endovascular repair also creates long-term monitoring demand. U.S. evidence indicates that EVAR accounts for approximately 80% of intact AAA repairs and 52% of ruptured repairs, creating follow-up requirements for endoleaks, aneurysm growth and device durability.

 

Carotid Ultrasound Demand Depends on Clinical Indications

Carotid ultrasound contributes meaningful demand, but routine screening of the general asymptomatic population is not recommended in the United States because false-positive findings and unnecessary procedures can outweigh the benefits.

Commercial demand comes from patients with transient ischemic attack or stroke symptoms, abnormal findings, known vascular disease, preoperative requirements and post-intervention surveillance needs.

A global modeling study estimated that 57.79 million people aged 30 to 79 had carotid stenosis of at least 50% in 2020. The realistic market is concentrated in hospitals, vascular laboratories, neurology services, cardiology practices and vascular-surgery clinics where testing is linked to a clinical decision.

 

Recurring Monitoring Generates Stronger Revenue Visibility

Repeat examinations provide the most attractive demand. A normal AAA screen may not require another test, while a detected aneurysm can create years of surveillance. PAD patients may be reassessed after supervised exercise, medication changes or revascularization, while carotid and lower-extremity procedures create repeat imaging demand.

Post-procedure monitoring is tied to an established diagnosis and defined care pathway, making these examinations more likely to be scheduled and reimbursed than broad preventive testing.

Manufacturers can also generate recurring revenue through cuffs, probes, accessories, software, maintenance, training and replacement platforms. Disposable cuffs may gain importance in wound-care and hospital settings where reusable accessories are less practical.

 

Automation, Connectivity and Portability Are Reshaping Procurement

The market is moving toward connected platforms with automated cuff inflation, guided test sequences, digital reports and electronic health-record integration. Newman Medical offers automated ABI configurations with reporting and connectivity, while MESI combines wireless ABI and TBI measurement with digital diagnostic modules. Philips and GE HealthCare compete through vascular imaging platforms supported by hospital relationships, service contracts and enterprise software.

Portable systems extend testing into podiatry, primary care, diabetes clinics, wound-care centers, nursing facilities and mobile programs. Their success depends on consistent results, simple workflows and reliable referral arrangements rather than portability alone.

 

Competitive Landscape

D. E. Hokanson supplies ABI, TBI, vascular Dopplers, cuffs and mobile physiological systems. Newman Medical offers manual and automated ABI systems and vascular Dopplers. Viasonix provides platforms covering ABI, TBI, segmental pressures, Doppler, pulse-volume recording and photoplethysmography.

MESI competes through a connected platform combining automated vascular assessments with other primary-care diagnostic tools. Huntleigh Diagnostics participates through handheld Dopplers, ABI equipment and reporting products. GE HealthCare and Philips address the market through hospital and specialist ultrasound portfolios.

Competition centers on workflow efficiency, test breadth, software connectivity, service coverage and outpatient distribution. Companies combining equipment with training, reporting, maintenance and accessories can capture a larger share of the care pathway.

 

End-User Dynamics

Hospitals and vascular laboratories perform the most complex examinations and surveillance work, using higher-value systems across PAD, carotid, aneurysm, graft and post-intervention assessment.

Primary-care practices have access to high-risk patients but may lack testing experience, appointment time or a clear reimbursement pathway. Podiatry, diabetology and wound-care clinics form an important PAD channel because poor circulation affects healing and treatment decisions, while TBI and waveform assessments are useful when ankle measurements are difficult to interpret.

Cardiology and vascular-surgery clinics use these devices within broader cardiovascular assessment and surveillance programs. Community and mobile services can improve geographic access, although sustainability depends on patient volume, funding and effective follow-up.

 

Regional Outlook

North America benefits from a large PAD population, established vascular laboratories, broad ultrasound access and a defined AAA screening recommendation. A published geographic benchmark valued the U.S. market at USD 458.9 million in 2024, approximately 27% of that benchmark’s global revenue. Canada is projected to expand at a 3.3% CAGR through 2030. Growth is moderated by fragmented reimbursement and the absence of support for mass asymptomatic carotid screening.

Europe includes organized AAA screening programs, with England showing how national invitations, quality standards and surveillance databases translate eligibility into measurable examination volume. Adoption differs by country because procurement and screening policies are not uniform.

Asia Pacific has long-term need driven by diabetes, smoking, hypertension and population ageing. China is projected to reach USD 444.3 million by 2030 in one geographic forecast, expanding at a 7.8% CAGR, while Japan is projected to grow at 1.7%. Regional expansion will therefore be concentrated in markets adding diagnostic capacity rather than evenly distributed across mature healthcare systems.

Latin America, the Middle East and Africa present demand for lower-cost Doppler and physiological systems where premium ultrasound access is limited. Distributor strength, clinician training and treatment availability will determine sustained demand.

 

Market Segmentation

By product type, the market includes ABI and TBI systems, handheld vascular Dopplers, duplex and color-Doppler ultrasound systems, pulse-volume-recording and photoplethysmography platforms, and related cuffs, probes, software and accessories. Portable and standalone configurations form the principal commercial split, with portable systems showing the stronger published growth rate.

By application, the market covers PAD assessment, AAA screening and surveillance, clinically indicated carotid assessment, post-revascularization monitoring, diabetic-foot and wound-related vascular assessment, and adjacent venous or dialysis-access examinations.

Major end users include hospitals, vascular laboratories, diagnostic imaging centers, cardiology and vascular-surgery clinics, primary-care practices, podiatry and diabetes clinics, wound-care centers, and community screening programs.

 

Market Outlook

Growth will depend on how effectively providers convert high-risk patients into appropriate testing and long-term surveillance. PAD provides the largest patient base, AAA offers the clearest organized screening pathway, and carotid ultrasound supports specialist demand tied to symptoms, findings and follow-up care.

Revenue growth will favor platforms that deliver consistent tests, reduce staff burden, integrate with clinical systems and support multiple vascular assessments. Manufacturers combining equipment with software, training, service and accessories will be better positioned than suppliers competing only on initial price.

The projected expansion from USD 2.27 billion in 2025 to USD 3.86 billion by 2032 represents an additional USD 1.59 billion in annual market revenue. The 7.9% CAGR reflects rising vascular disease burden, wider outpatient testing, greater use of automated physiological systems and recurring surveillance after diagnosis or intervention.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.27 Billion
Revenue Forecast in 2032	USD 3.86 Billion
Overall Growth Rate	CAGR of 7.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	ABI and TBI Systems, Handheld Vascular Dopplers, Duplex and Color-Doppler Ultrasound Systems, Pulse-Volume Recording and Photoplethysmography Systems, Cuffs, Probes, Software and Accessories
By Application	Peripheral Artery Disease Assessment, Abdominal Aortic Aneurysm Screening and Surveillance, Carotid Artery Assessment, Post-Revascularization Monitoring, Diabetic-Foot and Wound-Related Vascular Assessment
By End User	Hospitals and Vascular Laboratories, Diagnostic Imaging Centers, Cardiology and Vascular-Surgery Clinics, Primary-Care Practices, Podiatry, Diabetes and Wound-Care Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing clinical focus on early detection of peripheral vascular disease; rising prevalence of diabetes and related lower-limb complications; wider use of non-invasive vascular assessment in primary-care and specialty settings; increasing demand for portable Doppler, ABI, TBI and ultrasound-based screening systems
Customization Option	Available upon request